[Clinical-pharmacological effective data on 3',4',-dipropionylhelveticosol].
In experiments of treatment carried out on 39 patients with cardiac insufficiency with tachyarrhythmia for the partially synthetic, new heart glycoside 3',4'-dipropionyl helveticosol the following clinico-pharmacological data of efficacy were approximately established on an average: level of full efficacy 2.7 mg, daily coefficient of disappearing 40%, coefficient of enteral absorption 30%, daily maintenance dose intravenously 1.1 mg and orally 3.7 mg.
D000328:Adult; D002297:Cardanolides / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004071:Digitalis Glycosides / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D013610:Tachycardia / Q000188:drug therapy
D002297:Cardanolides; D004071:Digitalis Glycosides
Klinisch-pharmakologische Wirkdaten von 3',4'-Dipropionylhelvetikosol